Mibefradil has 3 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Lurasidone Hydrochloride, Paricalcitol, Pravastatin Sodium. Patients taking Mibefradil should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 3
- Contraindicated
- 1
- Major
- 1
- Moderate
- 1
Contraindicated (1)
- Mibefradil + Lurasidone Hydrochloride— Strong CYP3A4 inhibitor that increases lurasidone exposure; concomitant use is contraindicated.
Major (1)
- Mibefradil + Paricalcitol— Strong CYP3A inhibitor increases paricalcitol exposure. Dose adjustment may be necessary; monitor intact PTH and serum c…
Moderate (1)
- Mibefradil + Pravastatin Sodium— Cytochrome P450 3A4 inhibitor that may increase pravastatin bioavailability.